title: Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation.
abstract: BACKGROUND
  A pretransplant lymphocyte crossmatch (XM) test is usually considered mandatory but may delay deceased donor renal transplantation. We report on the safety and clinical efficacy of omitting the XM when it is predicted to be negative based on sensitization history and human leukocyte antigen-specific antibody screening.
  
  
  METHODS
  From 1998 to 2008, 606 deceased donor kidney transplants were performed at our center and the prospective donor-recipient XM omitted in 257 (42%). In all cases, a negative XM was confirmed retrospectively. Four hundred fourteen (68%) kidneys were donated after brain death (DBD) and 192 (32%) after cardiac death (DCD). The effect of this policy on cold ischemia time (CIT), delayed graft function (DGF), and transplant survival was assessed.
  
  
  RESULTS
  Mean CIT was 16.7 hr with a prospective XM and 14.3 hr when it was omitted (P<0.001). The beneficial effect of omitting the XM on DGF was only apparent in recipients of DBD kidneys, where the DGF rate was 28% with a prospective XM and 18% without a prospective XM (P=0.03). The corresponding DGF rate in recipients of DCD kidneys was 52% with a prospective XM and 54% without a prospective XM. Logistic regression analysis, after adjustment for variables that influenced DGF, showed that the odds on suffering DGF were lower when the pretransplant XM test was omitted (P=0.04). Neither acute rejection rate nor long-term graft survival was influenced by omission of the XM.
  
  
  CONCLUSIONS
  Rigorous recording of potential allosensitizing events and comprehensive antibody screening allows the XM to be safely omitted in selected patients and this helps limit CIT and may reduce DGF.
authors.affiliation: Tissue Typing Laboratory, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom. craig.taylor@addenbrookes.nhs.uk
authors.forename: Craig J
authors.initials: CJ
authors.lastname: Taylor
authors.forename: Vasilis
authors.initials: V
authors.lastname: Kosmoliaptsis
authors.forename: Linda D
authors.initials: LD
authors.lastname: Sharples
authors.forename: Davide
authors.initials: D
authors.lastname: Prezzi
authors.forename: C Helen
authors.initials: CH
authors.lastname: Morgan
authors.forename: Timothy
authors.initials: T
authors.lastname: Key
authors.forename: Afzal N
authors.initials: AN
authors.lastname: Chaudhry
authors.forename: Irum
authors.initials: I
authors.lastname: Amin
authors.forename: Menna R
authors.initials: MR
authors.lastname: Clatworthy
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Butler
authors.forename: Christopher J E
authors.initials: CJ
authors.lastname: Watson
authors.forename: J Andrew
authors.initials: JA
authors.lastname: Bradley
mesh_terms: D000328:Adult; D000368:Aged; D001926:Brain Death / Q000276:immunology; D002102:Cadaver; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology*; D006085:Graft Survival / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing / Q000379:methods; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D014019:Tissue Donors
chemical_list: D006680:HLA Antigens